cfDNA methylome profiling
cfMethyl-seq is an NGS solution for profiling the cfDNA methylome.
Source: LinkedIn company description · Retrieved October 13, 2026
EarlyDx provides non-invasive genomics technologies and early disease diagnostics.
The company combines cfDNA-based technologies with AI algorithms for biomarker discovery, diagnostics and precision medicine. The stated potential applications include cancer, aging, metabolic, autoimmune, imprinting and neurological diseases.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
cfMethyl-seq is an NGS solution for profiling the cfDNA methylome.
Source: LinkedIn company description · Retrieved October 13, 2026
EarlyDx-Cloud is a bioinformatics data analysis platform for liquid biopsy.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 19, 2026 and September 30, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.